

## Article Type: Research Letter

**Title:** Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study

Guihong Wan, PhD<sup>1,2\*</sup>, Nga Nguyen, MD, MPH<sup>1\*</sup>, Bonnie W. Leung, MD<sup>1</sup>, Hannah Rashdan, BS<sup>1</sup>, Kimberly Tang, BA<sup>1</sup>, Katie Roster, MS<sup>1</sup>, Michael R. Collier, BS<sup>1</sup>, Pearl O. Ugwu-Dike, BS<sup>1</sup>, Neel S. Raval, BA<sup>1</sup>, Nora A. Alexander, BS<sup>1</sup>, Ruple Jairath, BS<sup>1</sup>, Jordan Phillipps, BS<sup>1</sup>, Munachimso Amadife, BS<sup>1</sup>, Shijia Zhang, MBI<sup>1</sup>, Alexander Gusev, PhD<sup>3</sup>, Steven T. Chen, MD<sup>1</sup>, Kerry L. Reynolds, MD<sup>4</sup>, Nicole R. LeBoeuf, MD, MPH<sup>5</sup>, Shawn G. Kwatra, MD<sup>6\*\*</sup>, Yevgeniy R. Semenov, MD, MA<sup>1,2\*\*</sup>

<sup>1</sup> Massachusetts General Hospital, Department of Dermatology, Boston, MA

<sup>2</sup> Harvard Medical School, Department of Dermatology, Boston, MA

<sup>3</sup> Dana Farber Cancer Institute, Department of Medicine, Boston, MA

<sup>4</sup> Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston, MA

<sup>5</sup> Dana Farber Cancer Institute, Department of Dermatology, Boston, MA

<sup>6</sup> Johns Hopkins University, Department of Dermatology, Baltimore, MD

\*Designate co-first authors

\*\*Designates co-senior authors

Twitter handle: @EugeneSemenovMD

### Corresponding author:

Yevgeniy R. Semenov, MD, MA  
Department of Dermatology  
Massachusetts General Hospital  
Harvard Medical School  
40 Blossom Street  
Bartlett Hall 6R, Room 626  
Boston, MA 02114  
Email: [ysemenov@mgh.harvard.edu](mailto:ysemenov@mgh.harvard.edu)

**Funding Sources:** YRS is supported in part by the Department of Defense under Award Number W81XWH2110819, the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23 AR080791, and the Melanoma Research Alliance Young Investigator Award. SGK is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23AR077073. NRL is supported by NIH/NCI grant U54-CA225088. The other authors received no funding for this research. The content is solely the responsibility of the authors and does not represent the official views of the funders.

**Conflict of Interest:** YRS is an advisory board member/consultant and has received honoraria from Incyte Corporation, Castle Biosciences, Galderma, Pfizer, and Sanofi outside the submitted work. SGK is an advisory board member/consultant for Abbvie, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi. NRL is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics outside the submitted work.

**Reprint requests:** Yevgeniy R. Semenov, MD, MA

**IRB approval status:** Reviewed and approved by Mass General Brigham Institutional Review Board (Protocol # 2020P002307)

**Patient consent on file:** N/A

**Manuscript word count:** 497

**References:** 5

**Figures:** 0

**Tables:** 2

Supplementary methods: 2

Supplementary figures: 1

Supplementary tables: 6

**Keywords:**

pre-existing inflammatory disease; autoimmunity; cutaneous immune-related adverse events; cutaneous adverse reactions; immunotherapy; immune checkpoint inhibitor; oncodermatology

## **Abstract:**

*Background:* Relationships between pre-existing inflammatory diseases (pIDs) and cutaneous immune-related adverse events (cirAEs) have not been well-studied. This study is to investigate associations between pIDs and cirAEs among immune-checkpoint inhibitor (ICI) recipients at the Mass General Brigham healthcare system.

*Methods:* Electronic health records were reviewed to ascertain cirAE status. Patients' pID status was determined using International Classification of Diseases (ICD) codes. Cox proportional hazard, logistic regression, and linear regression models were performed.

*Results:* Among 3607 ICI recipients, 1354 had pIDs, and 672 developed cirAEs. After covariate adjustments, patients with cutaneous pIDs (HR:1.56,  $p<0.001$ ) or both cutaneous and non-cutaneous pIDs (HR:1.76,  $p<0.001$ ) had increased cirAE risk in contrast to patients with non-cutaneous pIDs alone (HR:1.01,  $p=0.9$ ). In adjusted ordinal logistic regression modeling, cutaneous pIDs (OR:1.55,  $p<0.0001$ ) and the presence of both cutaneous pIDs and non-cutaneous pIDs (OR:1.71,  $p=0.002$ ) were associated with increased cirAE severity. The time to cirAE onset was different between the cutaneous pID group and the non-cutaneous pID group (Mean: 98 vs. 146 days,  $p=0.021$ ; Beta: -0.11,  $p=0.033$ ).

*Conclusions:* ICI recipients with cutaneous pIDs should have increased clinical monitoring due to their increased risk of cirAE development, severity, and earlier onset.

Though immune checkpoint inhibitors (ICIs) have considerably improved patient outcomes, they are associated with morbid and potentially life-threatening immune-related adverse events (irAEs). As a result of the immune-mediated nature of these toxicities and despite recent evidence that ICI recipients with pre-existing inflammatory diseases (pIDs) are not at increased risk of mortality<sup>2,3</sup>, patients with pIDs have been largely excluded from ICI clinical trials, and data on toxicity development in this population is lacking.<sup>1</sup> To address this question, we leverage a large multi-institutional cohort of ICI recipients to examine associations of pIDs with cutaneous irAEs (cirAEs), which are the most common and earliest toxicities to occur with ICI therapy.

The presence, severity, and timing of cirAEs were ascertained by manual chart review using previously published approaches (**eMethod 1**).<sup>4,5</sup> Patients' pID status was determined using International Classification of Diseases (ICD) codes according to consensus definitions for inflammatory disorders (**eMethod 2**). Multivariate Cox Proportional Hazard (CoxPH) models were utilized to investigate relationships between pIDs and cirAEs. Hazard Ratios (HRs) and 95% confidence intervals (CIs) were computed. Adjusted logistic and linear regressions were used to examine associations of pIDs with cirAE severity and timing.

We identified 3,607 ICI recipients at the Massachusetts General Brigham (MGB) (**eFigure 1**). Among them, 1,354 (37.5%) had pIDs, and 672 (18.6%) developed cirAEs (**eTable 3**). In the pID group, 517 (38.2%) had one or more cutaneous pIDs (c-pIDs), and 837 (61.8%) had only non-cutaneous pIDs (nc-pIDs). Multivariate CoxPH modeling suggests that patients with pIDs were more likely to develop cirAEs (HR:1.20, 95% CI: [1.01, 1.42], p=0.036) (**Table 1**) compared to patients without pIDs. Specifically, c-pIDs increased the cirAE risk (HR:1.56, 95% CI: [1.25, 1.94], p<0.001), whereas nc-pIDs did not (HR:1.01, 95% CI: [0.82, 1.25], p=0.9). The cirAE risk was highest for patients with both c-pIDs and nc-pIDs (HR:1.76, 95% CI: [1.28, 2.42], p<0.001). This was most significant among patients with specific pre-existing dermatologic conditions, including atopic dermatitis (HR:3.58, 95% CI: [2.34, 5.48], p<0.001), morphea (HR:

3.23, 95% CI: [1.42, 7.37],  $p=0.005$ ), and psoriasis (HR:1.79, 95% CI: [1.23, 2.62],  $p=0.003$ ).

Sensitivity analyses yielded similar conclusions (**eTables 5-6**).

Furthermore, c-pIDs were associated with a higher risk of severe cirAEs (**Table 2**). In adjusted ordinal logistic regression modeling, c-pIDs (OR:1.55, 95% CI: [1.22, 1.96],  $p<0.0001$ ) and the presence of both c-pIDs and nc-pIDs (OR:1.71, 95% CI: [1.21, 2.38],  $P=0.002$ ) were associated with increased cirAE severity. The time to cirAE onset was different between the c-pID group and the nc-pID group (Mean: 98 vs. 146 days,  $p=0.021$ ; Beta: -0.11, 95% CI: [-0.21, -0.01],  $p=0.033$ ) (**eTable 4**).

This study demonstrated that increased cirAE risk was observed specifically in patients with c-pIDs, suggesting that immune-mediated predisposition to cirAE development is organ specific with possible tissue-specific or HLA-associated immunogenetic susceptibilities. Moreover, we identified an accentuated risk for high-grade (grade 3 or higher) and earlier onset cirAEs among patients with c-pIDs compared to those with nc-pIDs. The limitations of our study include use of ICD codes for pID status and retrospective grading of cutaneous eruptions.

**Table 1.** Associations of pIDs with cirAE development

Pre-existing disease <sup>a</sup>	Hazard Ratio	95% CI	p-value	q-value <sup>b</sup>	Patients with pIDs <sup>c</sup>	Patients with pIDs and cirAE <sup>d</sup>
Any pID	1.20	1.01, 1.42	<b>0.036</b>	0.068	1,354 (37.5%)	246 (18.2%)
Cutaneous pIDs	1.56	1.25, 1.94	<b>&lt;0.001</b>	<b>&lt;0.001</b>	517 (14.3%)	114 (22.1%)
Non-cutaneous pIDs	1.01	0.82, 1.25	>0.9	>0.9	837 (23.2%)	321 (15.8%)
Both Cutaneous and Non-cutaneous pIDs	1.76	1.28, 2.42	<b>&lt;0.001</b>	<b>0.003</b>	237 (6.6%)	52 (21.9%)
Atopic dermatitis	3.58	2.34, 5.48	<b>&lt;0.001</b>	<b>&lt;0.001</b>	62 (1.7%)	24 (38.7%)
Morphea	3.23	1.42, 7.37	<b>0.005</b>	<b>0.017</b>	20 (0.6%)	6 (30%)
Psoriasis	1.79	1.23, 2.62	<b>0.003</b>	<b>0.011</b>	124 (3.4%)	30 (24.2%)
Pemphigus	35.2	4.08, 304	<b>0.001</b>	<b>0.005</b>	1 (0.03%)	1 (100%)
Bullous pemphigoid	9.54	1.22, 74.4	<b>0.031</b>	0.068	2 (0.1%)	1 (50%)
Vitiligo	2.32	1.02, 5.24	<b>0.044</b>	0.094	14 (0.4%)	6 (42.9%)
Alopecia areata	2.08	0.51, 8.48	0.3	0.5	7 (0.2%)	2 (28.6%)
Polymyalgia rheumatica	2.11	1.10, 4.02	<b>0.024</b>	0.051	44 (1.2%)	10 (22.7%)
Systemic sclerosis	3.79	1.17, 12.3	<b>0.026</b>	0.062	7 (0.2%)	3 (42.9%)

<sup>a</sup> Each row corresponds to a separate multivariate Cox Proportional Hazard model to investigate the association of the grouped pre-existing inflammatory diseases (any pID, cutaneous pIDs, non-cutaneous pIDs, and both cutaneous and non-cutaneous pIDs) and individual inflammatory disease with cirAE development. Each model was adjusted by Race/Ethnicity, Sex, Charlson Comorbidity Index, Age at ICI Initiation, ICI Type, Year of ICI Initiation, and Cancer Category. All models have the same reference group, which is the population without any pID diagnosis.

<sup>b</sup> False discovery rate correction for multiple testing.

<sup>c</sup> Patients with pIDs: total number (percentage of the ICI population).

<sup>d</sup> Patients with pIDs and at least one cirAE: total number (percentage of the pID population).

pIDs: pre-existing inflammatory disease; cirAEs: cutaneous immune-related adverse events; CI: confidence interval.

**Table 2.** Impact of pIDs on the cirAE severity using logistic regression models

	<b>CirAE Severity Grade<sup>a</sup></b>	<b>Odds Ratio</b>	<b>95% CI</b>	<b>p-value</b>
Cutaneous pIDs	>=3	1.72	1.04, 2.76	0.029
	>=2	1.60	1.18, 2.15	0.002
	>=1	1.57	1.23, 2.00	<0.001
	Overall ordinal regression <sup>b</sup>	1.55	1.22, 1.96	<0.001
Both Cutaneous and Non-cutaneous pIDs	>=3	2.34	1.21, 4.25	0.008
	>=2	1.90	1.25, 2.84	0.002
	>=1	1.69	1.19, 2.37	0.003
	Overall ordinal regression <sup>b</sup>	1.71	1.21, 2.38	0.002

<sup>a</sup> Each row corresponds to a separate binomial or ordinal logistic regression model. Each model was adjusted by Race/Ethnicity, Sex, Charlson Comorbidity Index, Age at ICI Initiation, ICI Type, Year of ICI Initiation, and Cancer Category. All binomial models (>=3, >=2, and >=1) have the same reference group, which is the population without any pID diagnosis.

<sup>b</sup> Scale of cirAE severity: 1-4; No cirAE: 0.

pIDs: pre-existing inflammatory disease; cirAE: cutaneous immune-related adverse event; CI: confidence interval.

## References

1. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study. *Ann Intern Med*. May 2021;174(5):641-648. doi:10.7326/M20-3419
2. Tang K, Tiu BC, Wan G, et al. Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. *JNCI: Journal of the National Cancer Institute*. 2022;114(8):1200-1202. doi:10.1093/jnci/djac046
3. Tully KH, Cone EB, Cole AP, et al. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data. *Am J Clin Oncol*. Aug 1 2021;44(8):413-418. doi:10.1097/COC.0000000000000840
4. Zhang S, Tang K, Wan G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. *J Am Acad Dermatol*. Jan 31 2023;doi:10.1016/j.jaad.2022.12.048
5. Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/CTCAE\\_v5\\_Quick\\_Reference\\_8.5x11.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf)